MosheChaimOrnsteinMDMA

PubMed

• Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohor...
  Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mark Stein, Jeffrey Sosman, Robert Alter, David J Peace, David Einstein, Paul J Catalano, Meredith M Regan, Michael ...> ;Journal for Immunotherapy of Cancer. 2024 Apr 11
• Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation D...
  Amanda Nizam, Ryan K Rader, Alice Tzeng, Wei Wei, Iris Yeong-Fung Sheng, Allison Martin, Christopher E Wee, Timothy D Gilligan, Shilpa Gupta, Moshe C Ornstein> ;Clinical Genitourinary Cancer. 2024 Apr 1
• PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy.
  Kevin Hakimi, Steven C Campbell, Nityam Rathi, Luke Wang, Margaret F Meagher, Brian I Rini, Moshe Ornstein, Rana R McKay, Ithaar H Derweesh, Mimi V Nguyen> ;BJU International. 2024 Apr 1
• Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma.
  James Schuster, Iris Y Sheng, Chandana A Reddy, Alok A Khorana, Amanda Nizam, Shilpa Gupta, Timothy Gilligan, Christopher E Wee, Tamara A Sussman, Amanda Bonham, Kimbe...> ;Clinical Genitourinary Cancer. 2024 Apr 1
• Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor.
  Moshe C Ornstein, Laura S Wood> ;Advances in Therapy. 2023 Sep 1
• 3 citations
  Targeting HIF-2 Alpha in Renal Cell Carcinoma.
  Ramsha Ahmed, Moshe C Ornstein> ;Current Treatment Options in Oncology. 2023 Sep 1
• Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor.
  Moshe C Ornstein, Laura S Wood> ;Advances in Therapy. 2023 Sep 1
• 2 citations
  Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
  Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein,...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
• 2 citations
  Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
  James Larkin, Mototsugu Oya, Marcella Martignoni, Fiona Thistlethwaite, Paul Nathan, Moshe C Ornstein, Thomas Powles, Kathryn E Beckermann, Arjun V Balar, David McDerm...> ;The Oncologist. 2023 Apr 6
• 1 citations
  Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Pro.
  Steven C Campbell, Moshe C Ornstein, Nityam Rathi> ;European Urology Open Science. 2022 Oct 1
• 6 citations
  Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
  Landon C Brown, Jason Zhu, Kunal Desai, Emily Kinsey, Chester Kao, Yong Hee Lee, Sarabjot Pabla, Matthew K Labriola, Jennifer Tran, Konstantin H Dragnev, Laura J Tafe,...> ;Journal for Immunotherapy of Cancer. 2022 Oct 1
• 5 citations
  Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors.
  Iris Y Sheng, Shilpa Gupta, Chandana A Reddy, Dana Angelini, Pauline Funchain, Tamara A Sussman, Joseph Sleiman, Moshe C Ornstein, Keith McCrae, Alok A Khorana> ;Targeted Oncology. 2022 Sep 1
• 8 citations
  Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma.
  Oscar Reig Torras, Akhilesh Mishra, Alana Christie, Tiffani McKenzie, Oreoluwa Onabolu, Nirmish Singla, Elizabeth R Plimack, Cristina Suárez, Moshe C Ornstein, R Kathe...> ;European Urology. 2022 Jun 1
• 6 citations
  Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate.
  Magdalena Rainey, Monica Nair, Elai Davicioni, Ewan A Gibb, Sean Williamson, Shilpa Gupta, Moshe Chaim Ornstein, Rahul Tendulkar, Christopher Weight, Jane K Nguyen, Er...> ;European Urology Focus. 2022 Nov 1
• 28 citations
  Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
  Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe Ornstein, M...> ;Journal of Clinical Oncology. 2022 Sep 1
• Studying the association between breast cancer and renal cell carcinoma
  Khalid A. Jazieh, Firas Baidoun, Nataly Valeria Torrejon, Zahi Merjaneh, Anas M. Saad, Mohamed M. Gad, Amal Farouk, Moshe Chaim Ornstein, Jame Abraham> ;Breast Cancer Research and Treatment. 2021 Dec 2
• Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma
  Scott Dawsey, Moshe Chaim Ornstein> ;Current Oncology. 2021 Nov 30
• 9 citations
  Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy.
  Iris Yeong Fung Sheng, Shilpa Gupta, Chandana A. Reddy, Dana E. Angelini, Pauline Funchain, Tamara A. Sussman, Joseph Sleiman, Moshe Chaim Ornstein, Keith R. McCrae, A...> ;Targeted Oncology. 2021 Nov 6
• Moving the Needle Toward Improved Survival in Metastatic Prostate Cancer.
  Moshe Chaim Ornstein> ;JCO Oncology Practice. 2021 Oct 7
• 7 citations
  Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis.
  Alice Tzeng, Tony H. Tzeng, Moshe Chaim Ornstein> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
• 55 citations
  Clinical Review on the Management of Metastatic Renal Cell Carcinoma.
  Jennifer Tran, Moshe Chaim Ornstein> ;JCO Oncology Practice. 2021 Sep 16
• 9 citations
  Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
  Landon Carter Brown, Kunal Desai, Wei Wei, Emily N. Kinsey, Chester Kao, Daniel J. George, Brian I. Rini, Moshe Chaim Ornstein, Tian Zhang> ;Journal for Immunotherapy of Cancer. 2021 Sep 1
• 9 citations
  A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.
  Kunal Desai, Landon C. Brown, Wei Wei, Matthew D. Tucker, Chester Kao, Emily N. Kinsey, Brian I. Rini, Kathryn E. Beckermann, Tian Zhang, Moshe Chaim Ornstein> ;Targeted Oncology. 2021 Aug 11
• 5 citations
  Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature.
  Scott J. Dawsey, Steven C. Campbell, Moshe Chaim Ornstein> ;Current Oncology. 2021 May 20
• 12 citations
  Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
  Gregory R. Pond, Archana Agarwal, Moshe Chaim Ornstein, Jorge A. Garcia, Ruby Gupta, Petros Grivas, Alexandra Drakaki, Jae-Lyun Lee, Ravindran Kanesvaran, Giuseppe Di ...> ;Clinical Genitourinary Cancer. 2021 Apr 20
• Join now to see all

Lectures

• Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 inhibit... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018